Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data

GK Dawwas, CE Leonard, JD Lewis… - Annals of internal …, 2022 - acpjournals.org
Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the
treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons …
被引用次数：40 相关文章
[PDF] caregate.net

[PDF][PDF] Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data

GK Dawwas, CE Leonard, JD Lewis… - Annals of Internal …, 2022 - phdres.caregate.net
Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the
treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons …

[引用][C] Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data

GK Dawwas, CE Leonard, JD Lewis… - Annals of Internal …, 2022 - cir.nii.ac.jp
Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With
Rivaroxaban: An Analysis of Real-World Data | CiNii Research CiNii 国立情報学研究所 学術 …

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.

GK Dawwas, CE Leonard, JD Lewis… - Annals of Internal …, 2021 - europepmc.org
Background Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment
of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain …

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data

GK Dawwas, CE Leonard… - Annals of internal …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment
of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain …